Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan plus oxaliplatin versus docetaxel plus oxaliplatin in advanced epithelial ovarian cancer
ChiCTR-OCH-13004042Phase 4Completed
- Sponsor
- Hebei Cancer Hospital
- Start
- Dec 2013
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of irinotecan, oxaliplatin and docetaxel in epithelial ovarian cancer (EOC) and ovarian cancer (2 arms), sponsored by Hebei Cancer Hospital. Primary endpoints: Curative effect and Safety. Started Dec 2013; status: completed.
02
Drugs
irinotecanoxaliplatindocetaxel
03
Conditions
epithelial ovarian cancer (EOC)ovarian cancer
Beyond the preview
Go deeper on ChiCTR-OCH-13004042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OCH-13004042.